Immunome Inc
Immunome, Inc. (IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today the firm announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors.

The trial met its primary . . .